HYROTROPIN-secreting adenomas are rare, accounting for approximately 1 to 2 % of all pituitary adenomas. 2, 11, 18 The SITS by pituitary adenoma results in central hyperthyroidism, but the diagnosis may often be delayed. Such patients are often mistakenly treated for Graves disease and have long histories of thyroid dysfunction. Consequently, many thyrotropin-secreting adenomas are found when they are already large, invasive, and difficult to cure by surgery. 10, 11, 18 Most reports 10,12,16 describe a poor outcome from surgery, radiation therapy, or a combination of these modalities. Although the recent introduction of the ultrasensitive immunometric thyrotropin assay has enabled thyrotropin-secreting adenomas to be recognized more often, they remain uncommon and are unfamiliar to most neurosurgeons. The number of reported cases has tripled since 1990, 11 but those reports have mainly focused on endocrinological diagnoses and criteria. The surgical aspects and outcomes have not been well documented.
Clinical Material and Methods

Patient Population
Sixteen patients (12 women and four men, ages 23-62 years, mean 41.2 years) with thyrotropin pituitary adenomas were included in this study. These 16 patients represented 1.8% of 890 patients who underwent transsphenoidal surgery performed by the senior author (A.T.) between 1983 and 1999. Partial data on eight of these patients (Cases 1-8) have been previously reported. 20 All patients underwent a complete physical examination, including palpation of the thyroid and visual field testing using Goldman's perimetry. Serum thyrotropin levels were measured by highly specific immunoradiometric assay (AxSYM TSH Dainapack; Dainabot Co., Ltd., Tokyo, Japan), with detection limits of 0.005 U/ml. Measurements of the serum ␣ subunit of glycoprotein, free T 4 , and free T 3 were also performed using radioimmunoassay. The ␣ subunit/thyrotropin molar ratio was calculated according to the following molecular weight values: thyrotropin, 28,000 (1 g thyrotropin corresponding to 4.93 U) and ␣ subunit, 14,700. 15 Other basal hormone levels studied included GH, PRL, ACTH, LH, FSH, and serum free cortisol. As for endocrinological loading tests, TRH, bromocriptine, and octreotide tests were performed. The thyrotropin level was measured at 0, 30, 60, and 120 minutes after 500 g of the hormone was injected intravenously, whereas thyrotropin and PRL levels were measured before and at 2, 4, 6, and 12 hours after oral administration of 2.5 mg bromocriptine. Octreotide testing was performed in 12 patients: thyrotropin and GH levels were measured before and 2, 4, 6, and 12 hours after 50 g of octreotide was injected intravenously. As for the T 3 suppression test, patients received T 3 for 3 days, with the thyrotropin level measured before and after the T 3 treatment.
A contrast-enhanced CT scan of the pituitary gland was obtained in all patients, and 1.5-tesla MR images were obtained in 14 patients. Coronal and sagittal T 1 -weighted MR images were obtained before and after gadolinium injection. In the eight most recently treated patients, a serial thin-slice dynamic enhancement MR study of the pituitary gland was obtained.
Transsphenoidal resections of the adenomas were performed by the senior author at Tokyo Metropolitan Hospital or Toranomon Hospital and Nippon Medical School.
Histopathological Studies
Specimens obtained at surgery were fixed immediately in 10% buffered formalin or 4% paraformaldehyde and then embedded in paraffin. For immunohistochemical characterization of cellular hormonal contents, the indirect immunoperoxidase method was applied in formalin-fixed paraffin-embedded tissue. The following antisera were applied: anti-thyrotropin ␤ (1:3200 dilution); anti-␣ subunit of glycoprotein (1:200); FSH␤ (1:200); LH␤ (1:200; National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases, Bethesda, MD); GH (1:800); PRL (1: 600), and ACTH (1:800; Dako Corp., Carpinteria, CA). An MIB-1 immunohistochemical analysis was also performed using MIB-1 monoclonal antibody (1:50 dilution; Immunotech, Marseilles, France) and the MIB-1 index was calculated as a percentage of MIB-1-positive cells in more than 2000 tumor cells chosen from randomly selected fields.
Follow-Up Review
Serum thyrotropin, free T 3 , free T 4 , ACTH, cortisol, GH, and PRL were measured at 1 and 2 weeks postsurgery. A TRH stimulating test was performed 2 weeks postsurgery. Patients were followed up in the outpatient clinic of our institute or affiliated hospitals. Serum thyrotropin, free T 3 , and free T 4 levels were examined every 6 to 12 months, and other hormones, including ACTH, cortisol, GH, and PRL, were measured if necessary.
All patients underwent CT or MR imaging 1 to 2 weeks after their operation. Follow-up images were obtained over 3 months postoperatively in 14 patients.
Results
Clinical Features
The clinical profiles of the patients are shown in Tables  1 and 2 . Symptoms of severe hyperthyroidism were found in five patients, mild symptoms in 10, and absence of symptoms in one incidentally identified patient (Case 7). Signs of other hormone abnormalities were observed in four patients; that is, acromegalic features were seen in two (Cases 2 and 5) and amenorrhea-galactorrhea was present in two (Cases 4 and 14). Four of the 16 patients had undergone previous subtotal thyroidectomy and/or radioiodine thyroid ablation and 11 (68.8%) of 16 had been treated with antithyroid medication (methimazole). A goiter was present in 14 patients (87.5%).
All patients showed inappropriately elevated or detectable serum thyrotropin levels despite elevated thyroid hormones. Serum thyrotropin levels ranged from 0.67 to 55 U/ml, and the ␣ subunit level was elevated (0.2-9.8 ng/ml). A molar ratio of ␣ subunit/thyrotropin greater than 1.0 is indicative of the presence of thyrotropinsecreting adenoma; the ratios were greater than 1.0 in 13 patients. Elevated serum GH was noted in three patients (Cases 2, 5, and 8), and elevated PRL levels were noted in three patients (Cases 4, 14, and 16). Basal serum hormone levels of ACTH, cortisol, FSH, and LH were within normal ranges in all patients.
After TRH stimulation, serum thyrotropin levels increased in six patients, and no significant responses were seen in 10. After bromocriptine testing, a significant suppression (Ͻ 50% from the baseline level) was observed in two of 16 patients, whereas the other 14 patients showed partial to minimal suppression. Administration of octreotide resulted in significant thyrotropin suppression in 11 (91.7%) of 12 patients.
Results of other endocrinological tests, including PRL response to TRH (500 g administered intravenously), ACTH and cortisol response to corticotropin-releasing factor (100 g given intravenously), FSH and LH responses to LH-releasing hormone (100 g administered intravenously) were normal in all patients.
Radiological investigations, including CT and MR imaging, revealed the presence of pituitary mass lesions in all patients. These consisted of two microadenomas and 14 macroadenomas (Fig. 1 ). Cavernous sinus invasion was observed in 10 patients.
Operative Findings
All 16 patients underwent transsphenoidal surgery. Intraoperative findings revealed that the adenomas were well demarcated with normal anterior pituitary gland, and 13 (81.2%) of 16 were fibrous and firm, in contrast with other types of adenomas. Five tumors were so hard that they had to be resected piecemeal by using scissors and a knife. Dural invasion was observed in 12 of 16 adenomas. Total resection of the tumor was achieved in two microadenomas and six intrasellar-type tumors, and more than 80% of the tumor mass was resected in another five macroadenomas (Cases 1, 5, 6, 12, and 16). In three patients with larger and invasive tumors, the resection was less than 80% of tumor mass (Cases 2-4).
Postoperative Complications
There were no deaths related to surgery in this series. A transient incidence of diabetes insipidus occurred in one patient. Other complications, including cerebrospinal fluid leakage, visual disturbance, and postoperative bleeding, were not observed. Postoperative isolated persistent central hypothyroidism was found in three patients and panhypopituitarism was observed in one. In these patients hormone replacement therapy with levothyroxine with or without hydrocortisone was administered.
Histopathological Findings
Histopathological studies revealed that all specimens obtained in the 16 patients were pituitary adenomas. In 11 of 16 tissue samples relatively scattered tumor cells were surrounded by abundant connective tissues (Fig. 2) . Dural invasion was also confirmed by histological observation. Immunohistochemically, thyrotropin ␤ and ␣ subunit were positive in all 16 adenoma tissues. In addition, GH was positive in eight patients and PRL was positive in seven. The expression of Pit-1 protein was observed in all adenomas in many nuclei of the tumor cells. The MIB-1 positive index ranged from 0.6 to 1.2%. The details of the immunohistochemical results in Cases 1 to 4 have been previously reported. 19 In situ hybridization was performed in six patients (Cases 7-12) with biotinylated oligonucleo- 3) normal 0.8-1.9 0.34-3.5 0.1-1.3 Ͻ1.0 range * BC = bromocriptine; ND = not done or data not obtained; ϩ = significant suppression (Ͻ 50% of basal thyrotropin level); Ϫ = no significant suppression.
† Dosages: octreotide = 50 g intravenously; bromocriptine = 2.5 mg orally.
‡ Thyrotropin level was not suppressed by T 3 administration.
tide probes in paraffin sections, and the hybridization signal for thyrotropin ␤ mRNA, ␣ subunit mRNA, and Pit-1 mRNA was demonstrated in all 10 patients examined.
Treatment Outcome
Serum thyrotropin levels in all patients were reduced compared with preoperative levels at 1 week postsurgery. In 12 patients, serum thyrotropin levels were normalized (Table 3 ). In one patient (Case 1) the thyrotropin level was not normalized, with subnormal free T 3 and T 4 levels. These readings were considered to be due to hypothyroidism, and thyroxine replacement was required in that patient.
In 11 (68.8%) of 16 patients remission by surgery alone was attained. Criteria for surgical remission were not only total resection of tumor mass with reduction of serum thyrotropin, free T 3 , and free T 4 levels, but also normalization of SITS. Normalized postoperative ␣ subunit/thyrotropin molar ratios were obtained in eight of 11 patients. The dynamic test administered after surgery revealed normalization of responsiveness to TRH in three of 10 patients.
Total remission was achieved in 14 patients (87.5%). Criteria for remission were the normalization of hyperthyroidism with or without residual tumor on MR imaging. In six patients residual tumors were seen on MR imaging. External radiation of the pituitary gland (50.6 Gy) was performed after surgery in Case 4.
All patients underwent CT or MR imaging before discharge. Follow-up images were obtained more than 3 months after operation in 10 patients. Recurrence or regrowth of tumor was not found in this series during follow-up periods of 4 months to 15 years. The recurrence of SITS was found in two patients without tumor regrowth by radiological evaluation (Cases 7 and 12). One patient (Case 7) received bromocriptine (2.5-5 mg/day) and then achieved remission. The other (Case 12) achieved remission after receiving 50 Gy of irradiation. Despite remission of SITS after surgery, a primary hyperthyroidism remained in two patients (Cases 5 and 8). These patients had undetectably low levels of thyrotropin with elevated free T 4 ; therefore, coexistence of a primary hypothyroidism was suspected.
Illustrative Cases
Case 5
In this patient the coexistence of thyrotropin-secreting adenoma and primary hyperthyroidism was demonstrated. She presented with hyperthyroid syndrome, underwent subtotal thyroidectomy at 35 years of age, and received subsequent iodine-131 therapy. However, the hyperthyroid syndrome was not controlled. At the age of 45 years, she displayed SITS, and a CT scan and MR image obtained at that time revealed an encased macroadenoma
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Surgical outcome of thyrotropin adenomas 15 ϫ 11 ϫ 13 mm in size. Transsphenoidal surgery was performed in December 1991. The tumor was unusually firm and fibrous, and could not be suctioned or removed with curettes. The margin of the tumor was well demarcated, and the lesion was resected en bloc. Subtotal resection was confirmed on MR imaging postoperatively. A histopathological examination revealed that the tumor was positive for thyrotropin ␤ and ␣ subunit. Serum thyrotropin and free T 4 concentrations were normalized after removal of the tumor. Three months later, the hyperthyroid symptoms recurred with no concomitant increase in serum thyrotropin. At 10 months postoperatively, the patient's serum thyrotropin level was below 0.03 U/ml, but free T 3 and T 4 levels were as high as 13.8 pg/ml and 5.12 ng/dl, respectively. It is suggested that the patient had hyperthyroidism caused by excessive thyrotropin secretion from the pituitary adenoma, and subsequently developed Graves disease. During 9 years of follow up, she has continuously received antithyroid drug therapy. Recurrent pituitary tumor has not been found on CT scans or MR images.
Case 16
This case illustrated that the preoperative octreotide administration was effective in reducing serum thyroid hormone and thyrotropin levels as well as inducing tumor shrinkage. This 62-year-old woman presented with a 5-year history of tachycardia and atrial fibrillation. We diagnosed Graves disease, and she received antithyroid medication for 3 years. A CT scan and MR image demonstrated a macroadenoma. Her serum thyrotropin level was 5.37 U/ml and ␣ subunit was elevated to 8.66 ng/ml. The basal thyrotropin level showed no suppression by exogenous T 3 (50 g daily for 5 days) and a limited response to TRH administration. Octreotide in doses of 300 g given daily for 5 days reduced thyrotropin to 0.14 U/ml, with suppression of free T 3 and free T 4 levels. Followup MR images obtained after octreotide therapy revealed an approximately 20% shrinkage of the tumor (Fig. 3) .
She underwent transsphenoidal surgery uneventfully, and a hard and fibrous tumor was resected. Histopathological examination revealed that the tumor was positive for thyrotropin ␤ and ␣ subunit. Removal of 90% of the tumor mass resulted in a decrease in thyrotropin to 0.08 U/ml and ␣ subunit to 0.58 ng/ml, as well as subnormal serum free T 3 and free T 4 levels.
Discussion
Thyrotropin-secreting pituitary adenomas have been increasingly reported because of wider recognition of this rare disorder and the introduction of hypersensitive thyrotropin tests. The classic diagnostic criteria for thyrotropinsecreting adenomas are the presence of SITS, despite increased free thyroid hormone concentrations, and evidence of a pituitary tumor on CT and/or MR imaging. 6, 15 A molar ratio of ␣ subunit/thyrotropin greater than 1.0 is indicative of the presence of thyrotropin-secreting adenoma. 3, 4, 14 In our series, the ratios were greater than 1.0 in 13 patients, except in one patient with previous thyroid ablation. Some exceptional cases with previous thyroid treatment have been reported. 4 In our Case 10, the serum thyrotropin level was 0.672 U/ml, which was within normal limits. This patient was mistakenly believed to have a thyrotropin-secreting adenoma because of results of a T 3 suppression test, the ␣ subunit/thyrotropin ratio, and an immunohistochemical study of the adenoma tissue. It has been reported that 23 to 26% of patients with thyrotropinsecreting adenomas have normal thyrotropin levels.
2,11
Most patients with thyrotropin-secreting adenomas are still misdiagnosed initially and are inappropriately treated with antithyroid medication, subtotal thyroidectomy, or iodine-131 ablation. Previous therapy directed at decreasing endogenous thyroid hormone synthesis might promote tumor growth and autonomy, analogous to the development of Nelson syndrome after adrenalectomy for Cushing disease. In our series, four patients had undergone previous subtotal thyroidectomy and/or radioiodine thyroid ablation, and 11 patients had been treated with antithyroid medication. During surgery their tumors proved to be unusually hard and fibrous. Histopathological findings in the tumor showed abundant connective tissue among tumor cells, which was consistent with the surgical findings. Dural invasion was also confirmed on histopathological examination. Those histopathological features of thyrotropin-secreting adenomas may be one of the reasons for an increase in the difficulty of total tumor removal. A recent report from the National Institutes of Health stated that the main prognostic factors are size and invasiveness of the tumor, duration of symptoms, and intensity of hyperthyroidism. 6 In our cases, severe hyperthyroidism was seen in three patients, and they were difficult to cure, which was in agreement with their reports. Resectability may depend on the size and invasiveness of the tumor. In other words, duration of symptoms and previous therapy may influence the tumor firmness and the amount of connective tissue contained within.
However, resectability of the tumor does not always parallel its prognosis. For example, in the patient in Case 6 tumor resection was 80%, and residual tumor was seen on postoperative MR imaging; but clinically SITS was normalized and remission was achieved. Furthermore, in the patients in Cases 5 and 8, despite subtotal and total resection, respectively, of tumors and normalization of thyrotropin, hyperthyroid symptoms recurred without SITS. As indicated in previous reports, 9, 13 it is suggested that those patients had thyrotropin-secreting adenomas associated with Graves disease. Long-term thyrotropin stimulation may promote primary hyperthyroidism.
From our observations during surgery we conclude that previous thyroid ablation or antithyroid medication may influence tumor resectability and outcome. Surgical findings in thyrotropin-secreting tumors have shown them to be firm and not treatable with suction. This tendency was particularly enhanced in patients who had undergone preoperative thyroid ablation or antithyroid therapy and who had a long preoperative history of hyperthyroidism.
The rate of surgical remission in our study (62.5%) was higher than in other series. 1, 6, [15] [16] [17] We believe that two of the reasons for the higher rate of remission in our series are the relatively small tumor size and early diagnosis. Our earlier patients (Cases 1-5), who had long histories of hyperthyroidism and invasive microadenomas, could not achieve good outcomes.
In a significant percentage of patients with thyrotropinsecreting adenomas, thyroid toxicosis is severe, and control of hyperthyroid symptoms is necessary before surgery. Even in such patients, the use of antithyroid drugs should be avoided. Somatostatin analog treatment is potentially useful as a preparation for surgery. In our Case 16, preoperative administration of octreotide resulted in good control of thyrotropin and hyperthyroidism as well as tumor shrinkage. Presurgical octreotide treatment for acromegaly has been reported to be useful because of its ability to reduce pituitary tumor size and suprasellar extension and/or cavernous sinus compression, as well as its hormonal parameter. 22 It has been reported that octreotide does not induce tumor fibrosis, as does bromocriptine in PRL-secreting adenomas. In our patients, an octreotide administration test reduced serum thyrotropin levels below 50% of the baseline in 11 of 12 patients. The high concentration of somatostatin receptors in thyrotropinsecreting adenomas is responsible for the thyrotropin reduction. 5 In most previous reports it has been concluded that octreotide is effective in decreasing the thyrotropin level and controlling hyperthyroidism in thyrotropin-secreting adenomas. 7, 8, 23 Shrinkage of the adenoma has also been observed. 19, 24 It may be one of the choices of combination therapy in patients in whom it is difficult to achieve remission by surgery. Dopamine D 2 receptors have also been detected on thyrotropin-secreting adenomas, 24 but it is reported that the success of treatment is limited. The bromocriptine administration test showed significant reduction of thyrotropin in only one of 11 patients. One patient (Case 7) is considered an exception because bromocriptine was effective in combination with surgery.
From our observations, together with those in previous reports, heterogeneity in clinical presentation, hormone expression, morphological features, and therapeutic response seem to be the characteristics of thyrotropin-secreting adenomas. 1, 19, 21 In addition, thyrotropin-secreting adenomas have a fibrous and firm nature, which makes it difficult to achieve surgical remission. Although complete resection of thyrotropin-secreting adenomas is difficult to accomplish even for experienced pituitary surgeons, endocrinological remission can be obtained with surgery if tumors are found before they become larger invasive lesions. Of course, early diagnosis and early surgery are most important for successful treatment. We also have documented that even satisfactory resection of tumors sometimes results in recurrence of SITS or hyperthyroid symptoms due to coexistent primary hyperthyroidism. A careful follow up is necessary after surgery.
